The first dose of a copycat weight-loss drug Lindsay Posey took from a new pharmacy worked well. The second didn’t quite suppress her appetite. It was the third dose that she thinks caused her trouble.
Share of Eli Lilly surged on their latest Q1 2024 earnings results. Damien Conover, director of healthcare equity research at Morningstar, joins BNN Bloomberg to explain why he still has a sell rating on the stock.
Her doctor suggested it might have been a problem with the medicine itself. “That’s not really something you want to hear,” Posey said. It’s nearly impossible to know who’s taking these drugs. Compounded medications are generally not paid for by insurance, putting them out of view of systems that normally track prescriptions. The FDA doesn’t monitor how many prescriptions are filled for compounded drugs and at least 20 state boards of pharmacy told Bloomberg they’re not keeping a record either.
Stephen Peacock, chief medical officer of Henry Meds, said patients might prefer their offerings because they’re afraid of needles. When asked what data Henry Meds has to show their dissolving drugs are as effective as the shots, he didn’t provide any. Discussing the caliber of the company’s products, he said “I’m very confident in the safety and efficacy of our medications.”
Compounders started to work on a bigger scale in the 1990s and early 2000s, raising concerns. But lawmakers’ attempts to reform the system were successfully fought by pharmacies, resulting in scatter-shot regulation. That came to a head in 2012, when at least 64 people died and over 700 got sick from contaminated compounded drugs made by one pharmacy.
Consumer Goods Retail Consumer Staples Company News Biotech & Pharma General Government Health Care Industry North America Top News Unites States World Top World
Canada Latest News, Canada Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Cosmetic Ozempic Use Under Fire in Europe Amid Drug ShortagesThe European Union’s drug regulator urged countries to clamp down on cosmetic use of powerful drugs for weight loss and diabetes, saying that patients who need the medicines most must get priority as shortages continue.
Read more »
Wegovy Users Drop $80,000 on Plastic Surgery to Shed Extra SkinDoctors are seeing more post-Ozempic demand for tummy tucks, thigh lifts and facial fillers.
Read more »
Ozempic Maker Novo Nordisk Plans Another $4.1 Billion US FactoryNovo Nordisk A/S plans to invest $4.1 billion in another US factory, plowing more money into its biggest market amid rising discontent there over the cost of its obesity and diabetes drugs.
Read more »
Your Good Health: Diabetic patient wants to switch from metformin to OzempicThe data in people with diabetes show that compared to medicines like glipizide, medicines like semaglutide have significant benefit.
Read more »
Most patients stop using Wegovy, Ozempic for weight loss within two years, analysis findsEvidence that many people may stop using the weight-loss therapies not long after starting is influencing a debate over their cost to patients, employers and government health plans
Read more »
Exclusive-Most patients stop using Wegovy, Ozempic for weight loss within two years, analysis findsOnly one in four U.S. patients prescribed Novo Nordisk’s Wegovy or Ozempic for weight loss were still taking the popular medications two years later...
Read more »